Form 4: C4 Therapeutics Director Acquires Shares

C4 Therapeutics, Inc. reports that Director Donna Roy Grogan acquired 5,370 shares of common stock on April 1, 2026, as part of her compensation.

Summary

• Donna Roy Grogan, a Director at C4 Therapeutics, Inc., acquired 5,370 shares of common stock on April 1, 2026.
• This acquisition was made in lieu of cash compensation as per the Issuer's Non-Employee Director Compensation Policy.
• The shares were valued at $2.70 each, based on the closing market price on the transaction date.
• Following this transaction, Ms. Grogan beneficially owns 71,512 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine compensation-related transaction by a director and does not inherently signal positive or negative performance.

Positives

• Director compensation aligns with company policy, indicating a structured approach to director remuneration.
• The transaction reflects continued directorship and potential confidence in the company's future by a board member.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings of company directors and officers. This specific filing indicates a routine compensation-related share acquisition by a director.

Stakeholder Impact

• Shareholders: Increased transparency regarding director holdings. The acquisition is part of a pre-defined compensation policy, suggesting no immediate impact on share price due to this specific event.

Key Dates

Keywords

C4 Therapeutics, Donna Roy Grogan, Form 4, SEC Filing, Director Compensation, Common Stock, Beneficial Ownership